The Indian pharmaceuticals market is estimated to have reach $28.8bn in 2018 and is expected to grow at a CAGR of 16.6% in the first half of the forecast period. The market for cardiovascular medication is the fastest growing segment of the Indian pharmaceutical market, followed by the anti-infective segment. How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 212-page report you will receive 121 charts– all unavailable elsewhere.
The 212-page report provides clear detailed insight into the Indian Pharmaceutical Market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Indian Pharmaceuticals Market forecasts from 2019-2029
• Revenue forecasts for the leading therapeutic areas in India from 2019-2029: • Anti-Infectives Therapeutics • Cardiovascular Therapeutics • Dermatological Therapeutics • Diabetes Therapeutics • Gastrointestinal Therapeutics • Gynaecology Therapeutics • CNS Therapeutics • Pain Relief/Analgesics Therapeutics • Respiratory Therapeutics • Vitamins/Minerals/Nutrients Therapeutics • Other Therapeutics
This report also discusses factors that drive and restrain these submarkets.
• Revenue forecasts for the leading drug types in India from 2019-2029: • Generic Drugs • Over-the-Counter (OTC) Drugs • Patented Drugs • Biosimilar Drugs
This report also discusses factors that drive and restrain these submarkets.
• Profiles and discusses the leading companies in the Indian pharmaceutical market: • Abbott Healthcare Private Limited (Abbott India) • Cadila Healthcare Limited • Cipla Ltd. • Dr. Reddy’s Laboratories Ltd. • GlaxoSmithKline Pharmaceuticals Limited • Glenmark Pharmaceuticals Limited • Intas Pharmaceuticals Limited • Lupin • Pfizer Limited • Sanofi India Limited • Sun Pharmaceuticals Industries Limited
(Revenues are provided for those companies whose financial information is available on the public domain)
• Analysis of the drivers and restraints of the Indian Pharmaceutical market • The report also discusses the Porter’s Five Forces Analysis and SWOT Analysis of the Indian Pharmaceuticals Market
• This report also discusses: • Indian healthcare system and Indian healthcare expenditure • Indian pharmaceutical regulatory framework, laws & regulations, market access, regulatory bodies • Disease prevalence and incidence in India, disease mortality rates in India, top causes of death in India, mortality projections from 2019-2029
• What this report provides: • The Indian pharmaceutical market forecasts and analysis from 2019 to 2029 • Analysis and forecasts for the Indian pharmaceutical submarkets from 2019 to 2029 • Profiles of the leading companies operating within the Indian pharmaceutical industry • SWOT analysis and Porter’s five forces analysis of the major strengths and weaknesses of the Indian pharmaceutical market together with the opportunities available and the key threats faced
Visiongain’s study is intended for anyone requiring commercial analyses for the Indian Pharmaceuticals Market. You find data, trends and predictions.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 The Indian Pharmaceutical Market Overview
1.2 Indian Pharmaceutical Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
Table 8.1 Top 50 Companies in the Indian Pharmaceutical Market: Revenue (Rs. m), Revenue ($m) and Market Share (%), 2017
Table 8.2 Sun Pharmaceuticals: Revenue (Rs. m), Revenue ($m) and Revenue Share (%) by Business Area, FY 2017
Table 8.3 Sun Pharmaceuticals: Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
Table 8.4 Sun Pharmaceuticals: M&A Activity, 1997-2016
Table 8.5 Abbott India: Market Share (%) and Market Rank of Key Brands
Table 8.6 Abbott India: Revenue (Rs. m), AGR (%) and CAGR (%), 2006-2017
Table 8.7 Cipla: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
Table 8.8 Cipla: Revenue (Rs. m), Revenue ($m) and Revenue Share (%) by Geographical Area, 2017
Table 8.9 Cadila Healthcare Ltd.: Total Revenue (Rs. m), Total Revenue ($m), AGR (%) and CAGR (%), 2008-2017
Table 8.10 Cadila Healthcare Ltd.: Revenue (Rs.m) and Revenue Share (%) by Therapeutic Area, 2017
Table 8.11 GlaxoSmithKline India: Key Products in the Indian Market, 2017
Table 8.12 GlaxoSmithKline India Total Revenue (Rs. m), AGR (%) and CAGR (%), 2007-2017
Table 8.13 Pfizer India: Leading Brands on the Indian Market 2017
Table 8.14 Pfizer India: Total Revenue (Rs.m), AGR (%) and CAGR (%), 2008-2017
Table 8.15 Lupin: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
Table 8.16 Lupin: Revenue Share (%) by Therapeutic Area, 2017
Table 8.17 Sanofi India Limited: Major Products,2017
Table 8.18 Sanofi India Limited: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
Table 8.19 Sanofi India Limited: Revenue (Rs. m) and Revenue Share (%) by Domestic Segment, 2017
Table 8.20 Sanofi India Limited: Revenue (Rs. m) and Revenue Share (%) by Branded drugs, 2017
Table 8.21 Sanofi India Limited: Revenue (Rs. m), and Revenue Share (%) by Geographical Area, 2017
Table 8.22 Intas Pharmaceuticals Limited: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
Table 8.23 Dr. Reddy’s Laboratories Ltd: Major Products,2017
Table 8.24 Dr. Reddy’s Laboratories Ltd: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
Table 8.25 Dr. Reddy’s Laboratories Ltd: Revenue (Rs. m), and Revenue Share (%) by Business Segment, 2017
Table 8.26 Dr. Reddy’s Laboratories Ltd: Revenue (Rs.m), and Revenue Share (%) by Geographical Area, 2017
Table 8.27 Glenmark Pharmaceuticals Limited: Total Revenue (Rs.m), AGR (%) and CAGR (%), 2008-2017
Table 9.1 SWOT Analysis of the Indian Pharmaceuticals Market
List of Figures
Figure 1.1 Indian Pharmaceutical Market: Overview of Submarkets
Figure 2.1 Indian Population: Rural and Urban (Mn),1960-2020
Figure 2.2 Indian Population: Total (Mn) and Annual Population Growth Rate (%), 1960-2020
Figure 2.3 Indian GDP ($bn) and Growth Rate (%), 2010-2020
Figure 2.4 Access to Improved Water Sources as a Proportion of Total Population (%) and Access to Improved Sanitation as a Proportion of Total Population (%), 2008-2020
Figure 2.5 Indian GDP ($bn) and Health Expenditure as a Proportion of GDP (%), 2006-2014
Figure 2.6 Health Expenditure: Public Health expenditure as a Proportion of Total Health Expenditure (%) and Out of Pocket Expenditure as a Proportion of Private Health Expenditure 2008-2014
Figure 3.1 National Regulatory Bodies Regulating the Indian Pharmaceutical Market
Figure 4.1 The Indian Pharmaceutical Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 5.1 Leading Causes of Death in India, Proportion of Total Deaths (%) 2014
Figure 6.1 Leading Therapeutic Areas in the Indian Pharmaceuticals Market: Market Share (%), 2018
Figure 6.2 Leading Therapeutic Areas in the Indian Pharmaceuticals Market: Market Share (%), 2024
Figure 6.3 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2029
Figure 6.4 The Infectious Disease Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 6.5 Malaria cases (m), P. falciparum cases (m) and Proportion of P. falciparum cases (%) in India, 1995-2014
Figure 6.6 Infectious Diseases Therapeutics Market in India: Drivers and Restraints, 2018-2029
Figure 6.7 The Indian Cardiovascular Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 6.8 Cardiovascular Diseases Therapeutics Market in India: Drivers and Restraints
Figure 6.9 Indian Gastro-Intestinal Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 6.10 Gastro-intestinal Therapeutics Market in India: Drivers and Restraints
Figure 6.11 Indian Respiratory Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 6.12 Respiratory Therapeutics Market in India: Drivers and Restraints, 2018-2029
Figure 6.13 Indian Pain Relief/Analgesics Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 6.14 Pain Relief/Analgesics Therapeutics Market in India: Drivers and Restraints, 2018-2029
Figure 6.15 Indian Diabetes Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 6.16 Diabetes Therapeutics Market in India: Drivers and Restraints
Figure 6.17 Indian Vitamins / Minerals / Nutrients Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 6.18 Vitamins / Minerals / Nutrients Therapeutics Market in India: Drivers and Restraints
Figure 6.19 Indian Dermatological Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 6.20 Dermatological Therapeutics Market in India: Drivers and Restraints
Figure 6.21 Indian CNS Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 6.22 CNS Therapeutics Market in India: Drivers and Restraints
Figure 6.23 Indian Gynaecological Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 6.24 Gynaecological Therapeutics Market in India: Drivers and Restraints
Figure 6.25 Indian Other Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 7.1 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2019
Figure 7.2 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2024
Figure 7.3 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2029
Figure 7.4 Indian Generic Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 7.5 Generic Drugs Market in India: Drivers and Restraints
Figure 7.6 Indian OTC Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 7.7 OTC Drugs Market in India: Drivers and Restraints
Figure 7.8 Indian Patented Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 7.9 Patented Drugs Market in India: Drivers and Restraints
Figure 7.10 Indian Biosimilar Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
Figure 7.11 Biosimilar Drug Market in India: Drivers and Restraints
Figure 8.1 Sun Pharmaceuticals: Revenue Share (%) by Business Area, FY 2017
Figure 8.2 Sun Pharmaceuticals: Revenue ($m) and AGR (%), 2008-2017
Figure 8.3 Abbott India: Revenue (Rs. m) and AGR (%), 2006-2017
Figure 8.4 Cipla Revenue (Rs.m) and AGR (%), 2008-2017
Figure 8.5 Cadila Healthcare Ltd.: Revenue Share (%), by Business Area, 2017
Figure 8.6 GlaxoSmithKline India: Revenue ($m) and AGR (%), 2007-2017
Figure 8.7 Pfizer India: Revenue (Rs.m) and AGR (%), 2007-2016
Figure 8.8 Lupin: Revenue (Rs.m) and AGR (%), 2008-2017
Figure 8.9 Lupin: Revenue Share (%) by Therapeutic Area, 2017
Figure 8.10 Sanofi India Limited: Revenue ($m) and AGR (%), 2008-2017
Figure 8.11 Sanofi India Limited: Revenue Distribution by Business Segments, 2017
Figure 8.12 Sanofi India Limited: Revenue Distribution by Domestic Segments, 2017
Figure 8.13 Sanofi India Limited: Revenue Distribution by Geographical Area, 2017
The latest report from business intelligence provider visiongain offers comprehensive analysis of the global influenza vaccines market. Visiongain assesses that...
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
